Current status and future role of brain PET/MRI in clinical and research settings

详细信息    查看全文

• 作者：P. Werner (1)
  H. Barthel (1)
  A. Drzezga (2)
  O. Sabri (1)
  
  1. Department of Nuclear Medicine ; University Hospital Leipzig ; Liebigstr. 18 ; 04103 ; Leipzig ; Germany
  2. Department of Nuclear Medicine ; University Hospital Cologne ; 50937 ; K枚ln ; Germany
  
• 关键词：PET/MRI ; Dementia ; Brain tumours ; Stroke ; Functional MRI ; Molecular imaging
• 刊名：European Journal of Nuclear Medicine and Molecular Imaging
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：42
• 期：3
• 页码：512-526
• 全文大小：7,185 KB
• 参考文献：1. Dukart J, Mueller K, Horstmann A, Barthel H, M枚ller HE, Villringer A, et al. Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS One. 2011;6:e18111. CrossRef
  2. Jack Jr CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer鈥檚 disease and amnestic mild cognitive impairment. Brain J Neurol. 2008;131:665鈥?0. CrossRef
  3. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, M眉ller H-W, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain J Neurol. 2005;128:678鈥?7. CrossRef
  4. Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, et al. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery. 2009;64:471鈥?1; discussion 481. 227/01.NEU.0000338949.94496.85" target="_blank" title="It opens in new window">CrossRef
  5. Dunet V, Maeder P, Nicod-Lalonde M, Lhermitte B, Pollo C, Bloch J, et al. Combination of MRI and dynamic FET PET for initial glioma grading. Nuklearmedizin. 53:155鈥?1.
  6. Catana C, Drzezga A, Heiss W-D, Rosen BR. PET/MRI for neurologic applications. J Nucl Med. 2012;53:1916鈥?5. 2967/jnumed.112.105346" target="_blank" title="It opens in new window">CrossRef
  7. Heiss W-D. Radionuclide imaging in ischemic stroke. J Nucl Med. 2014;55:1831鈥?1. 2967/jnumed.114.145003" target="_blank" title="It opens in new window">CrossRef
  8. Zhang K, Herzog H, Mauler J, Filss C, Okell TW, Kops ER, et al. Comparison of cerebral blood flow acquired by simultaneous [15O]water positron emission tomography and arterial spin labeling magnetic resonance imaging. J Cereb Blood Flow Metab. 2014;34:1373鈥?0. 2014.92" target="_blank" title="It opens in new window">CrossRef
  9. Rischpler C, Nekolla SG, Dregely I, Schwaiger M. Hybrid PET/MR imaging of the heart: potential, initial experiences, and future prospects. J Nucl Med. 2013;54:402鈥?5. 2967/jnumed.112.105353" target="_blank" title="It opens in new window">CrossRef
  10. Bolus NE, George R, Washington J, Newcomer BR. PET/MRI: the blended-modality choice of the future? J Nucl Med Technol. 2009;37:63鈥?1. quiz 72鈥?3. 2967/jnmt.108.060848" target="_blank" title="It opens in new window">CrossRef
  11. Beyer T, Antoch G, M眉ller S, Egelhof T, Freudenberg LS, Debatin J, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med. 2004;45 Suppl 1:25S鈥?5.
  12. Gilmore CD, Comeau CR, Alessi AM, Blaine M, El Fakhri GN, Hunt JK, et al. PET/MR imaging consensus paper: a joint paper by the Society of Nuclear Medicine and Molecular Imaging Technologist Section and the Section for Magnetic Resonance Technologists. J Nucl Med Technol. 2013;41:108鈥?3. 2967/jnmt.113.123869" target="_blank" title="It opens in new window">CrossRef
  13. Carney JP, Townsend DW, Rappoport V, Bendriem B. Method for transforming CT images for attenuation correction in PET/CT imaging. Med Phys. 2006;33:976鈥?3. 2174132" target="_blank" title="It opens in new window">CrossRef
  14. Navalpakkam BK, Braun H, Kuwert T, Quick HH. Magnetic resonance-based attenuation correction for PET/MR hybrid imaging using continuous valued attenuation maps. Invest Radiol. 2013;48:323鈥?2. 283292f" target="_blank" title="It opens in new window">CrossRef
  15. Berker Y, Franke J, Salomon A, Palmowski M, Donker HC, Temur Y, et al. MRI-based attenuation correction for hybrid PET/MRI systems: a 4-class tissue segmentation technique using a combined ultrashort-echo-time/Dixon MRI sequence. J Nucl Med. 2012;53:796鈥?04. 2967/jnumed.111.092577" target="_blank" title="It opens in new window">CrossRef
  16. Andersen FL, Ladefoged CN, Beyer T, Keller SH, Hansen AE, H酶jgaard L, et al. Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. Neuroimage. 2014;84:206鈥?6. 2013.08.042" target="_blank" title="It opens in new window">CrossRef
  17. Keereman V, Fierens Y, Broux T, De Deene Y, Lonneux M, Vandenberghe S. MRI-based attenuation correction for PET/MRI using ultrashort echo time sequences. J Nucl Med. 2010;51:812鈥?. 2967/jnumed.109.065425" target="_blank" title="It opens in new window">CrossRef
  18. Poynton CB, Chen KT, Chonde DB, Izquierdo-Garcia D, Gollub RL, Gerstner ER, et al. Probabilistic atlas-based segmentation of combined T1-weighted and DUTE MRI for calculation of head attenuation maps in integrated PET/MRI scanners. Am J Nucl Med Mol Imaging. 2014;4:160鈥?1.
  19. Rezaei A, Defrise M, Nuyts J. ML-reconstruction for TOF-PET with simultaneous estimation of the attenuation factors. IEEE Trans Med Imaging. 2014;33:1563鈥?2. 2014.2318175" target="_blank" title="It opens in new window">CrossRef
  20. Delso G, F眉rst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med. 2011;52:1914鈥?2. 2967/jnumed.111.092726" target="_blank" title="It opens in new window">CrossRef
  21. Oakes TR, Johnstone T, Ores Walsh KS, Greischar LL, Alexander AL, Fox AS, et al. Comparison of fMRI motion correction software tools. Neuroimage. 2005;28:529鈥?3. 2005.05.058" target="_blank" title="It opens in new window">CrossRef
  22. Catana C, Benner T, van der Kouwe A, Byars L, Hamm M, Chonde DB, et al. MRI-assisted PET motion correction for neurologic studies in an integrated MR-PET scanner. J Nucl Med. 2011;52:154鈥?1. 2967/jnumed.110.079343" target="_blank" title="It opens in new window">CrossRef
  23. Fung EK, Carson RE. Cerebral blood flow with [15O]water PET studies using an image-derived input function and MR-defined carotid centerlines. Phys Med Biol. 2013;58:1903鈥?3. CrossRef
  24. Su Y, Arbelaez AM, Benzinger TLS, Snyder AZ, Vlassenko AG, Mintun MA, et al. Noninvasive estimation of the arterial input function in positron emission tomography imaging of cerebral blood flow. J Cereb Blood Flow Metab. 2013;33:115鈥?1. 2012.143" target="_blank" title="It opens in new window">CrossRef
  25. Olivot J-M, Mlynash M, Thijs VN, Kemp S, Lansberg MG, Wechsler L, et al. Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke J Cereb Circ. 2009;40:469鈥?5. 26954" target="_blank" title="It opens in new window">CrossRef
  26. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology. 1999;213:521鈥?. 213.2.r99nv37521" target="_blank" title="It opens in new window">CrossRef
  27. Chan T. Computerized method for automatic evaluation of lean body mass from PET/CT: comparison with predictive equations. J Nucl Med. 2012;53:130鈥?. 2967/jnumed.111.089292" target="_blank" title="It opens in new window">CrossRef
  28. Acosta-Cabronero J, Williams GB, Cardenas-Blanco A, Arnold RJ, Lupson V, Nestor PJ. In vivo quantitative susceptibility mapping (QSM) in Alzheimer鈥檚 disease. PLoS One. 2013;8:e81093. CrossRef
  29. Rivlin M, Horev J, Tsarfaty I, Navon G. Molecular imaging of tumors and metastases using chemical exchange saturation transfer (CEST) MRI. Sci Rep. 2013;3:3045. CrossRef
  30. Sorbi S, Hort J, Erkinjuntti T, Fladby T, Gainotti G, Gurvit H, et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19:1159鈥?9. 2012.03784.x" target="_blank" title="It opens in new window">CrossRef
  31. Frisoni GB, Fox NC, Jack Jr CR, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67鈥?7. 2009.215" target="_blank" title="It opens in new window">CrossRef
  32. Frisoni GB, Bocchetta M, Ch茅telat G, Rabinovici GD, de Leon MJ, Kaye J, et al. Imaging markers for Alzheimer disease: which vs how. Neurology. 2013;81:487鈥?00. 212/WNL.0b013e31829d86e8" target="_blank" title="It opens in new window">CrossRef
  33. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer鈥檚 pathological cascade. Lancet Neurol. 2010;9:119鈥?8. 22(09)70299-6" target="_blank" title="It opens in new window">CrossRef
  34. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer鈥檚 disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486鈥?10. 259-005-1762-7" target="_blank" title="It opens in new window">CrossRef
  35. Heiss WD, Kessler J, Szelies B, Grond M, Fink G, Herholz K. Positron emission tomography in the differential diagnosis of organic dementias. J Neural Transm Suppl. 1991;33:13鈥?.
  36. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer鈥檚 disease, and other dementias. J Nucl Med. 2008;49:390鈥?. 2967/jnumed.107.045385" target="_blank" title="It opens in new window">CrossRef
  37. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275鈥?3. 2010.2008" target="_blank" title="It opens in new window">CrossRef
  38. Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer鈥檚 disease. Eur J Nucl Med Mol Imaging. 2013;40:104鈥?4. 259-012-2237-2" target="_blank" title="It opens in new window">CrossRef
  39. Barthel H, Gertz H-J, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-尾 PET with florbetaben (18F) in patients with Alzheimer鈥檚 disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424鈥?5. 22(11)70077-1" target="_blank" title="It opens in new window">CrossRef
  40. Hsiao I-T, Huang C-C, Hsieh C-J, Hsu W-C, Wey S-P, Yen T-C, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012;39:613鈥?0. 259-011-2051-2" target="_blank" title="It opens in new window">CrossRef
  41. Jones DT, Machulda MM, Vemuri P, McDade EM, Zeng G, Senjem ML, et al. Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology. 2011;77:1524鈥?1. 212/WNL.0b013e318233b33d" target="_blank" title="It opens in new window">CrossRef
  42. Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010;67:584鈥?. 2009.08.024" target="_blank" title="It opens in new window">CrossRef
  43. Myers N, Pasquini L, G枚ttler J, Grimmer T, Koch K, Ortner M, et al. Within-patient correspondence of amyloid-尾 and intrinsic network connectivity in Alzheimer鈥檚 disease. Brain J Neurol. 2014;137:2052鈥?4. CrossRef
  44. Griffa A, Baumann PS, Thiran J-P, Hagmann P. Structural connectomics in brain diseases. Neuroimage. 2013;80:515鈥?6. 2013.04.056" target="_blank" title="It opens in new window">CrossRef
  45. Alsop DC, Dai W, Grossman M, Detre JA. Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimer鈥檚 disease. J Alzheimers Dis. 2010;20:871鈥?0.
  46. Kendziorra K, Wolf H, Meyer PM, Barthel H, Hesse S, Becker GA, et al. Decreased cerebral 伪4尾2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer鈥檚 disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging. 2011;38:515鈥?5. 259-010-1644-5" target="_blank" title="It opens in new window">CrossRef
  47. Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D, et al. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry. 2009;66:866鈥?7. 2009.106" target="_blank" title="It opens in new window">CrossRef
  48. Jagust W. Time for tau. Brain. 2014;137:1570鈥?. CrossRef
  49. Bailey DL, Barthel H, Beuthin-Baumann B, Beyer T, Bisdas S, Boellaard R, et al. Combined PET/MR: Where are we now? Summary report of the second international workshop on PET/MR imaging April 8-12, 2013, Tubingen, Germany. Mol Imaging Biol. 2014;16:295鈥?10
  50. Garibotto V, Heinzer S, Vulliemoz S, Guignard R, Wissmeyer M, Seeck M, et al. Clinical applications of hybrid PET/MRI in neuroimaging. Clin Nucl Med. 2013;38:e13鈥?. 2638ea6" target="_blank" title="It opens in new window">CrossRef
  51. Drzezga A, Barthel H, Minoshima S, Sabri O. Potential clinical applications of PET/MR imaging in neurodegenerative diseases. J Nucl Med. 2014;55 Suppl 2;47S鈥?7S. 2967/jnumed.113.129254" target="_blank" title="It opens in new window">CrossRef
  52. Schmidt H, Schwenzer NF, Bezrukov I, Mantlik F, Kolb A, Kupferschl盲ger J, et al. On the quantification accuracy, homogeneity, and stability of simultaneous positron emission tomography/magnetic resonance imaging systems. Invest Radiol. 2014;49:373鈥?1. 21" target="_blank" title="It opens in new window">CrossRef
  53. Hitz S, Habekost C, F眉rst S, Delso G, F枚rster S, Ziegler S, et al. Systematic comparison of the performance of integrated whole-body PET/MR imaging to conventional PET/CT for 18F-FDG brain imaging in patients examined for suspected dementia. J Nucl Med. 2014;55:923鈥?1. 2967/jnumed.113.126813" target="_blank" title="It opens in new window">CrossRef
  54. Barker 2nd FG, Chang SM, Huhn SL, Davis RL, Gutin PH, McDermott MW, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer. 1997;80:936鈥?1. 2/(SICI)1097-0142(19970901)80:5<936::AID-CNCR15>3.0.CO;2-X" target="_blank" title="It opens in new window">CrossRef
  55. Scott JN, Brasher PMA, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59:947鈥?. 212/WNL.59.6.947" target="_blank" title="It opens in new window">CrossRef
  56. Kruser TJ, Mehta MP, Robins HI. Pseudoprogression after glioma therapy: a comprehensive review. Expert Rev Neurother. 2013;13:389鈥?03. CrossRef
  57. Duffau H. A new philosophy in surgery for diffuse low-grade glioma (DLGG): oncological and functional outcomes. Neurochirurgie. 2013;59:2鈥?. 2012.11.001" target="_blank" title="It opens in new window">CrossRef
  58. Galldiks N, Kracht LW, Dunkl V, Ullrich RT, Vollmar S, Jacobs AH, et al. Imaging of non- or very subtle contrast-enhancing malignant gliomas with [11C]-methionine positron emission tomography. Mol Imaging. 2011;10:453鈥?.
  59. Galldiks N, Ullrich R, Schroeter M, Fink GR, Jacobs AH, Kracht LW. Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging. 2010;37:84鈥?2. 259-009-1219-5" target="_blank" title="It opens in new window">CrossRef
  60. Bangiyev L, Rossi Espagnet MC, Young R, Shepherd T, Knopp E, Friedman K, et al. Adult brain tumor imaging: state of the art. Semin Roentgenol. 2014;49:39鈥?2. 2013.11.001" target="_blank" title="It opens in new window">CrossRef
  61. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989鈥?8.
  62. Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004;25:746鈥?5.
  63. La Foug猫re C, Suchorska B, Bartenstein P, Kreth F-W, Tonn J-C. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol. 2011;13:806鈥?9. CrossRef
  64. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol. 2006;27:1432鈥?.
  65. Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009;50:1962鈥?. 2967/jnumed.109.065904" target="_blank" title="It opens in new window">CrossRef
  66. Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC. 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med. 2012;53:1709鈥?5. 2967/jnumed.111.102533" target="_blank" title="It opens in new window">CrossRef
  67. P枚pperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933鈥?2. 259-007-0534-y" target="_blank" title="It opens in new window">CrossRef
  68. Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol. 2011;13:307鈥?6. CrossRef
  69. Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med. 2004;45:1293鈥?.
  70. Purz S, Mauz-K枚rholz C, K枚rholz D, Hasenclever D, Krausse A, Sorge I, et al. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin鈥檚 lymphoma. J Clin Oncol. 2011;29:3523鈥?. 200/JCO.2010.32.4996" target="_blank" title="It opens in new window">CrossRef
  71. Grosu AL, Weber WA, Franz M, St盲rk S, Piert M, Thamm R, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:511鈥?. 2005.01.056" target="_blank" title="It opens in new window">CrossRef
  72. Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006;104:238鈥?3. 2006.104.2.238" target="_blank" title="It opens in new window">CrossRef
  73. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010;51:1198鈥?05. 2967/jnumed.110.074773" target="_blank" title="It opens in new window">CrossRef
  74. Bisdas S, Ritz R, Bender B, Braun C, Pfannenberg C, Reimold M, et al. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes. Invest Radiol. 2013;48:295鈥?01. 27188d6" target="_blank" title="It opens in new window">CrossRef
  75. Preuss M, Werner P, Barthel H, Nestler U, Christiansen H, Hirsch FW, et al. Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors. Childs Nerv Syst. 30:1399鈥?03.
  76. Werner P, Fritzsch D, Holland H, Bauer M, Krupp W, Hoffmann K-T, et al. Definition of primary and secondary glioblastoma 鈥?letter. Clin Cancer Res. 2014;20:2011鈥?. 2.CCR-13-3190" target="_blank" title="It opens in new window">CrossRef
  77. Sharma H. Multiparametric imaging and MR image texture analysis in brain tumors (PhD thesis). The University of Western Ontario; 2014.
  78. Artan Y, Yetik IS, Haider MA. Automated prostate cancer localization with multiparametric magnetic resonance imaging. In: El-Baz AS, Saba L, Suri JS, editors. Abdomen and thoracic imaging: an engineering and clinical perspective. New York: Springer; 2014. p. 559鈥?6. 22" target="_blank" title="It opens in new window">CrossRef
  79. Prior FW, Fouke SJ, Benzinger T, Boyd A, Chicoine M, Cholleti S, et al. Predicting a multi-parametric probability map of active tumor extent using random forests. Conf Proc IEEE Eng Med Biol Soc. 2013;2013:6478鈥?1.
  80. Hacke W, Kaste M, Bluhmki E, Brozman M, D谩valos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317鈥?9. CrossRef
  81. Heiss WD, Grond M, Thiel A, von Stockhausen HM, Rudolf J, Ghaemi M, et al. Tissue at risk of infarction rescued by early reperfusion: a positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke. J Cereb Blood Flow Metab. 1998;18:1298鈥?07. 2000-00004" target="_blank" title="It opens in new window">CrossRef
  82. Thijs VN, Adami A, Neumann-Haefelin T, Moseley ME, Marks MP, Albers GW. Relationship between severity of MR perfusion deficit and DWI lesion evolution. Neurology. 2001;57:1205鈥?1. 212/WNL.57.7.1205" target="_blank" title="It opens in new window">CrossRef
  83. Merino JG, Warach S. Imaging of acute stroke. Nat Rev Neurol. 2010;6:560鈥?1. 2010.129" target="_blank" title="It opens in new window">CrossRef
  84. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60:508鈥?7. 2/ana.20976" target="_blank" title="It opens in new window">CrossRef
  85. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8:141鈥?0. 22(08)70267-9" target="_blank" title="It opens in new window">CrossRef
  86. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al. Effects of alteplase beyond 3聽h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299鈥?09. 22(08)70044-9" target="_blank" title="It opens in new window">CrossRef
  87. Bokkers RP, Bremmer JP, van Berckel BNM, Lammertsma AA, Hendrikse J, Pluim JPW, et al. Arterial spin labeling perfusion MRI at multiple delay times: a correlative study with H(2)(15)O positron emission tomography in patients with symptomatic carotid artery occlusion. J Cereb Blood Flow Metab. 2010;30:222鈥?. 2009.204" target="_blank" title="It opens in new window">CrossRef
  88. Nael K, Meshksar A, Liebeskind DS, Coull BM, Krupinski EA, Villablanca JP. Quantitative analysis of hypoperfusion in acute stroke: arterial spin labeling versus dynamic susceptibility contrast. Stroke J Cereb Circ. 2013;44:3090鈥?. 2377" target="_blank" title="It opens in new window">CrossRef
  89. Zaro-Weber O, Moeller-Hartmann W, Heiss W-D, Sobesky J. Maps of time to maximum and time to peak for mismatch definition in clinical stroke studies validated with positron emission tomography. Stroke J Cereb Circ. 2010;41:2817鈥?1. 2" target="_blank" title="It opens in new window">CrossRef
  90. O鈥橞rien TJ, Hicks RJ, Ware R, Binns DS, Murphy M, Cook MJ. The utility of a 3-dimensional, large-field-of-view, sodium iodide crystal鈥揵ased PET scanner in the presurgical evaluation of partial epilepsy. J Nucl Med. 2001;42:1158鈥?5.
  91. Lee KK, Salamon N. [18F]fluorodeoxyglucose-positron-emission tomography and MR imaging coregistration for presurgical evaluation of medically refractory epilepsy. AJNR Am J Neuroradiol. 2009;30:1811鈥?. CrossRef
  92. LoPinto鈥怟houry C, Sperling MR, Skidmore C, Nei M, Evans J, Sharan A, et al. Surgical outcome in PET鈥恜ositive, MRI鈥恘egative patients with temporal lobe epilepsy. Epilepsia. 2012;53:342鈥?. 28-1167.2011.03359.x" target="_blank" title="It opens in new window">CrossRef
  93. Chassoux F, Rodrigo S, Semah F, Beuvon F, Landre E, Devaux B, et al. FDG-PET improves surgical outcome in negative MRI Taylor-type focal cortical dysplasias. Neurology. 2010;75:2168鈥?5. 212/WNL.0b013e31820203a9" target="_blank" title="It opens in new window">CrossRef
  94. Gok B, Jallo G, Hayeri R, Wahl R, Aygun N. The evaluation of FDG-PET imaging for epileptogenic focus localization in patients with MRI positive and MRI negative temporal lobe epilepsy. Neuroradiology. 2013;55:541鈥?0. 234-012-1121-x" target="_blank" title="It opens in new window">CrossRef
  95. Purz S, Sabri O, Viehweger A, Barthel H, Kluge R, Sorge I, et al. Potential pediatric applications of PET/MR. J Nucl Med. 2014;55 Suppl 2:32S鈥?9S. 2967/jnumed.113.129304" target="_blank" title="It opens in new window">CrossRef
  96. Sander CY, Hooker JM, Catana C, Normandin MD, Alpert NM, Knudsen GM, et al. Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. Proc Natl Acad Sci U S A. 2013;110:11169鈥?4. 220512110" target="_blank" title="It opens in new window">CrossRef
  97. Wehrl HF, Martirosian P, Schick F, Reischl G, Pichler BJ. Assessment of rodent brain activity using combined [(15)O]H2O-PET and BOLD-fMRI. Neuroimage. 2014;89:271鈥?. 2013.11.044" target="_blank" title="It opens in new window">CrossRef
  98. Wehrl HF, Hossain M, Lankes K, Liu C-C, Bezrukov I, Martirosian P, et al. Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales. Nat Med. 2013;19:1184鈥?. 290" target="_blank" title="It opens in new window">CrossRef
  99. Riedl V, Bienkowska K, Strobel C, Tahmasian M, Grimmer T, F枚rster S, et al. Local activity determines functional connectivity in the resting human brain: a simultaneous FDG-PET/fMRI study. J Neurosci. 2014;34:6260鈥?. 23/JNEUROSCI.0492-14.2014" target="_blank" title="It opens in new window">CrossRef
  100. Schultz CC, Fusar-Poli P, Wagner G, Koch K, Schachtzabel C, Gruber O, et al. Multimodal functional and structural imaging investigations in psychosis research. Eur Arch Psychiatry Clin Neurosci. 2012;262 Suppl 2:S97鈥?06. 2-0360-5" target="_blank" title="It opens in new window">CrossRef
  101. Uppal R, Catana C, Ay I, Benner T, Sorensen AG, Caravan P. Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrin-targeted dual PET/MR probe 鈥?feasibility study in rat model. Radiology. 2011;258:812鈥?0. CrossRef
  102. Morbelli S, Perneczky R, Drzezga A, Frisoni GB, Caroli A, van Berckel BN, et al. Metabolic networks underlying cognitive reserve in prodromal Alzheimer disease: a European Alzheimer disease consortium project. J Nucl Med. 2013;54:894鈥?02. 2967/jnumed.112.113928" target="_blank" title="It opens in new window">CrossRef
  103. Yakushev I, Ch茅telat G, Fischer FU, Landeau B, Bastin C, Scheurich A, et al. Metabolic and structural connectivity within the default mode network relates to working memory performance in young healthy adults. Neuroimage. 2013;79:184鈥?0. 2013.04.069" target="_blank" title="It opens in new window">CrossRef
  104. Villien M, Wey H-Y, Mandeville JB, Catana C, Polimeni JR, Sander CY, et al. Dynamic functional imaging of brain glucose utilization using fPET-FDG. Neuroimage. 2014;100:192鈥?. 2014.06.025" target="_blank" title="It opens in new window">CrossRef
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Nuclear Medicine
  Imaging and Radiology
  Orthopedics
  Cardiology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1619-7089

文摘

Hybrid PET/MRI systematically offers a complementary combination of two modalities that has often proven itself superior to the single modality approach in the diagnostic work-up of many neurological and psychiatric diseases. Emerging PET tracers, technical advances in multiparametric MRI and obvious workflow advantages may lead to a significant improvement in the diagnosis of dementia disorders, neurooncological diseases, epilepsy and neurovascular diseases using PET/MRI. Moreover, simultaneous PET/MRI is well suited to complex studies of brain function in which fast fluctuations of brain signals (e.g. related to task processing or in response to pharmacological interventions) need to be monitored on multiple levels. Initial simultaneous studies have already demonstrated that these complementary measures of brain function can provide new insights into the functional and structural organization of the brain.